These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28461199)

  • 41. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
    Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
    PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies.
    Dimasi N; Fleming R; Wu H; Gao C
    Methods; 2019 Feb; 154():77-86. PubMed ID: 30102989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?
    Maher J; Adami AA
    Cancer Res; 2013 Sep; 73(18):5613-7. PubMed ID: 24014596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant approaches to IgG-like bispecific antibodies.
    Marvin JS; Zhu Z
    Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Smarter drugs: a focus on pan-specific monoclonal antibodies.
    Fagète S; Fischer N
    BioDrugs; 2011 Dec; 25(6):357-64. PubMed ID: 22050338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic bispecific antibody formats: a patent applications review (1994-2017).
    Godar M; de Haard H; Blanchetot C; Rasser J
    Expert Opin Ther Pat; 2018 Mar; 28(3):251-276. PubMed ID: 29366356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
    Teillaud JL
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering].
    Asano R; Kumagai I
    Yakugaku Zasshi; 2015; 135(7):851-6. PubMed ID: 26135084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
    Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ
    Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Construction and production of an IgG-like tetravalent bispecific antibody for enhanced therapeutic efficacy.
    Lu D; Zhu Z
    Methods Mol Biol; 2009; 525():377-404, xiv. PubMed ID: 19252849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.